Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, +14

The Lancet Respiratory Medicine

MedicineRandomised Phase 3ImmunologyPathologyAlectinib Versus Crizotinib +7

X-ray-responsive selenium nanoparticles for enhanced cancer chemo-radiotherapy

Bo Yu, Ting Liu, Yanxin Du, +3

Colloids and Surfaces B Biointerfaces

NanoparticlesNanomedicineEngineeringNanomaterialsNanotechnology +5

Saikosaponin B2 ameliorates depression-induced microglia activation by inhibiting ferroptosis-mediated neuroinflammation and ER stress

Xinmei Wang, Shanshan Li, Jiayu Yu, +9

Journal of Ethnopharmacology

InflammationMedicineSaikosaponin B2PharmacologyBrain-immune Interaction +7

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

M. Pérol, Nick Pavlakis, E. Levchenko, +11

Lung Cancer

Patient-reported OutcomesMedicineCancer ManagementPathologyAlectinib Versus Crizotinib +4

Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study

Tony Mok, Solange Peters, D. Ross Camidge, +10

Journal of Thoracic Oncology

Identification and validation of EMT-immune-related prognostic biomarkers CDKN2A, CMTM8 and ILK in colon cancer

Ning Kang, Xiao‐Li Xie, Xue Zhou, +5

BMC Gastroenterology

Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy

Hang Ji, Yixu Ba, Shuai Ma, +11

Frontiers in Immunology

ImmunologyPathologyImmunologic MechanismHigh-grade GliomasImmunotherapy +18

Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer

Gaopeng Li, Guoliang Wang, Fenqing Chi, +19

Journal for ImmunoTherapy of Cancer

Alectinib versus crizotinib in treatment-naive advanced <i>ALK</i>-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.

Alice T. Shaw, Solange Peters, Tony Mok, +14

Journal of Clinical Oncology

Primary ResultsImmunologyPathologyCns ProgressionPharmacotherapy +17

Functionalized Low-Density Lipoprotein Nanoparticles for in Vivo Enhancement of Atherosclerosis on Magnetic Resonance Images

Andrew N. Lowell, Hui Qiao, Ting Liu, +8

Bioconjugate Chemistry